News
GVAX questions depress Dendreon shares
After halting one GVAX study so it could further investigate a disturbing number of deaths, Cell Genesys' hopes for the vaccine are now focused on a separate Phase III trial that has not raised the Read more...
Reversal of Fragile X symptoms a possibility
Canadian researchers say that it may be possible to compensate for the key brain protein missing in Fragile X patients, opening the way to a possible therapy that can reverse symptoms of the disease. Read more...
Cells coaxed to produce insulin in diabetes breakthrough
A team of scientists at the Harvard Stem Cell Institute have reprogrammed normal pancreas cells into insulin-producing cells in mice. The team injected proteins into the cells to activate genes, Read more...
ImClone builds case for higher takeover bid
The executives at ImClone have been carefully crunching the numbers for both its pipeline drugs as well as Read more...
Replidyne looking for buyer after latest job cuts
Another round of job cuts at the struggling Replidyne will leave only a skeleton staff of five on the payroll of a biotech company that once employed 85. Replidyne was dealt a crushing blow last year Read more...
Pfizer fails again in late-stage anti-clotting trial
There's more bad news for Pfizer's pipeline. An anti-clotting drug it is developing with Bristol-Myers Read more...
C&L: RHEI names new CEO
RHEI Pharmaceuticals has named Dr. Geert Cauwenbergh as CEO. Helicos BioSciences announced that Bill Efcavitch, Ph.D., has been named Helicos chief technology officer, Marc Levine has joined Helicos Read more...
Partners in pain target new drug
Pain Therapeutics and King Pharmaceuticals, which are already partnered in a major pain drug program, say they are developing a new abuse-resistant prescription pain medication called PTI-721. Like Read more...
FDA holds back approval for J&J schizophrenia med
The FDA has put up at least a temporary roadblock to J&J's schizophrenia drug paliperidone palmitate. A once-monthly injectable with the same active ingredient as Invega, a newly approved Read more...
Sangamo buoyed by positive mid-stage data
Shares of Sangamo BioSciences were buoyed by positive preliminary data from a small mid-stage study of SB-509. The drug is being tested as a therapy for severe diabetic neuropathy. In the study, five Read more...
NexMed tanks after Novartis stalls on fungus drug
Shares of NexMed tanked after the company announced late Tuesday that Novartis would not be submitting an NDA for their partnered nail fungus therapy "at this time." According to NexMed, Novartis was Read more...
Point BioMedical folds after investor pulls out
BioSpace takes a look today at the case of Point BioMedical, which is folding its tent after losing the backing of its lead investor. The biotech pulled its NDA for a molecular imaging product as is Read more...
'Brown fat' may be a key to curing obesity
By manipulating levels of the protein BMP-7, Harvard Medical School researchers were able to generate a larger store of "brown" fat cells that burn calories--a pathway that could be used to pursue Read more...
Azilect data points to Parkinson's efficacy
Teva Pharmaceutical is touting the results of a late-stage study of Azilect, a treatment for Parkinson's disease. Researchers say the therapy hit all of its goals in the ADAGIO trial. Patients taking Read more...
Galapagos buys structure-based drug discovery assets
Belgium's Galapagos NV has bought out Sareum's assets in drug discovery services for 695,000 euros. The assets will help position Galapagos' service division, BioFocus DPI, in the structure-based Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets